Deals
-
Courtesy of Ipsen
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.
By Delilah Alvarado • April 22, 2024 -
selvanegra via Getty Images
Eisai hunts for next Alzheimer’s drug with new research pact
A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.
By Jonathan Gardner • April 22, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive
TrendlineBiotech dealmaking
Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A.
By BioPharma Dive staff -
Courtesy of Teva Pharmaceutical
Alvotech deal could heighten biosimilar pressure on Humira
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.
By Jonathan Gardner • April 19, 2024 -
Nemes Laszlo via Getty Images
Roche, Adaptimmune part ways on cell therapy research
The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.
By Jacob Bell • April 12, 2024 -
luismmolina via Getty Images
Emerging biotechCentury buys a startup, raises funding in cell therapy expansion
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
By Delilah Alvarado • April 11, 2024 -
Permission granted by Vertex Pharmaceuticals
Vertex to buy kidney disease drugmaker Alpine for $4.9B
A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.
By Gwendolyn Wu • Updated April 11, 2024 -
Mario Tama via Getty Images
J&J to acquire Shockwave Medical for $13.1B
The deal comes just over a week after The Wall Street Journal reported the companies were discussing a merger.
By Ricky Zipp • Updated April 5, 2024 -
Love Employee via Getty Images
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.
By Kristin Jensen • April 3, 2024 -
Michael M. Santiago via Getty Images
Acorda files for bankruptcy, reveals asset sale plan
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
By Jacob Bell • April 2, 2024 -
Permission granted by Cardior
‘The heart is back,’ says Cardior CEO, as Novo’s $1B deal boosts field
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior head Claudia Ulbrich.
By Michael Gibney • March 28, 2024 -
Courtesy of AbbVie
AbbVie to buy immune drug developer Landos
Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.
By Delilah Alvarado • March 25, 2024 -
hapabapa via Getty Images
Novo to acquire heart failure drug in $1B deal for Cardior
Cardior’s therapy is currently in mid-stage testing and, should the deal close, Novo plans to start another Phase 2 trial.
By Ned Pagliarulo • March 25, 2024 -
Courtesy of Thermo Fisher Scientific
Thermo Fisher, Bayer partner to develop companion diagnostics
The companies aim to identify potential patients for Bayer’s precision cancer therapies and increase access to the treatments.
By Nick Paul Taylor • March 21, 2024 -
Dr_Microbe via Getty Images
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
The deal hands AstraZeneca a prostate cancer drug that’s designed differently than Novartis’ fast-selling Pluvicto and currently in mid-stage testing.
By Ben Fidler • March 19, 2024 -
dkfielding via Getty Images
BIO changes stance, backs bill to limit China’s role in US biotech
Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.
By Jonathan Gardner • March 14, 2024 -
Christopher Furlong via Getty Images
AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt
The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.
By Kristin Jensen • March 14, 2024 -
sudok1 via Getty Images
Boehringer, Sosei Heptares team up in schizophrenia drug deal
Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.
By Delilah Alvarado • March 11, 2024 -
Permission granted by Gilead Sciences
Gilead bets on ‘trispecifics’ in latest cancer drug deal
A small partnership with Merus adds to Gilead’s string of cancer dealmaking, which, so far, has not paid off for the large biotech.
By Jacob Bell • March 6, 2024 -
Permission granted by Gilead Sciences
Abingworth invests in Trodelvy development in deal with Gilead
One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.
By Kristin Jensen • Feb. 29, 2024 -
Spencer Platt via Getty Images
NGM to go private through deal with investment firm
The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.
By Jacob Bell • Feb. 26, 2024 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
AbbVie’s Cerevel deal hits an uncommon roadblock
A “second request” from the Federal Trade Commission could protract the timing of AbbVie’s proposed acquisition, which is slated to close around the middle of the year.
By Jacob Bell • Feb. 20, 2024 -
Dilok Klaisataporn
BioAge raises $170M to back Phase 2-ready obesity drug
BioAge’s Series D will fund a study combining its medicine with Eli Lilly’s Zepbound, a strategy the company hopes could help people lose weight while maintaining muscle mass.
By Jonathan Gardner • Feb. 13, 2024 -
Justin Sullivan via Getty Images
Gilead to buy CymaBay in $4.3B deal for liver disease drug
The proposed acquisition is a bet on CymaBay’s drug seladelpar, which is now under FDA review in a chronic liver disease called primary biliary cholangitis.
By Ned Pagliarulo • Feb. 12, 2024 -
Maximusnd via Getty Images
BridgeBio sells partial rights to dwarfism drug for $100M
The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.
By Delilah Alvarado • Feb. 7, 2024 -
Christopher Furlong via Getty Images
AstraZeneca to invest $300M in US cell therapy plant
The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.
By Kristin Jensen • Feb. 7, 2024
